Answers are grounded in this paper and cite their sources.
The central problem when delivering drugs to the brain is no longer crossing the blood-brain barrier, but delivering therapeutics to the right cells, in the right regions to target neurodegeneration, within a dynamically changing neurovascular unit.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: